je.st
news
Tag: biopharma
Galena Biopharma Earns "Buy" Rating from Roth Capital
2015-05-24 06:48:06| Biotech - Topix.net
's stock had its "buy" rating reiterated by equities researchers at Roth Capital in a research report issued on Friday. They currently have a $8.00 price target on the biotechnology company's stock.
Alexion Pharma to pay $8.4 billion for Synageva BioPharma
2015-05-06 18:14:05| Biotech - Topix.net
Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no products on the market.
Tags: pay
billion
pharma
biopharma
Sigma-Aldrich opens doors to latest Singapore biopharma investment
2015-04-22 08:07:25| Chemicals - Topix.net
Sigma-Aldrich has opened a cell culture Technical Center in Singapore and plans to expand further in the city-state with a cGMP distribution site. The site in Biopolis Research Park will offer customer's cell culture and pre-clinical services, as well as collaborating Sigma-Aldrich's existing Singaporean commercial offices and production laboratories into one location.
Tags: latest
investment
singapore
opens
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
2015-03-13 20:18:18| Biotech - Topix.net
Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced the pricing of an underwritten public offering of 24,358,974 units at a public offering price of $1.56 per unit, for total gross proceeds of $38.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $2.08 per share.
Tags: public
stock
common
offering
Galena Biopharma Enrolls 700th Patient in NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial
2015-02-09 18:35:24| Biotech - Topix.net
Galena Biopharma, Inc. , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced enrollment of the 700th patient in the NeuVax Phase 3 PRESENT clinical trial. NeuVax is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.
Tags: present
trial
phase
patient
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »